Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NutriBand Inc. (NTRB)

NutriBand Inc. amends $5 million three-year credit line at 7% interest

Neutral Impact 2 of 5 financing Written later

NutriBand Inc. entered into an amended three-year, $5,000,000 credit line on June 1, 2026, replacing a $5,000,000 facility from March 19, 2023 that was scheduled to expire July 13, 2026. The line is meant to fund the FDA approval process and commercial-scale manufacturing for its AVERSA Fentanyl product, and the filing states the lender cannot convert borrowings into common stock.

Key points

  • Three-year, $5,000,000 credit line entered June 1, 2026, replacing the March 19, 2023 facility
  • Drawdowns bear interest at 7% per annum
  • Lender cannot convert amounts outstanding under the line into common stock
  • Proceeds to support FDA approval and commercial-scale manufacturing of AVERSA Fentanyl

The filing

CompanyNutriBand Inc. (NTRB)
Form8-K, current report
Filed with the SECJun 22, 2026, 8:02 AM ET
Accession number0001213900-26-070378

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.